Sevoflo
Loading...Sevoflo Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Sevoflurane is a profound respiratory depressant.
DUE TO THE RAPID AND DOSE DEPENDENT CHANGES IN ANESTHETIC DEPTH, RESPIRATION MUST BE MONITORED CLOSELY IN THE DOG AND SUPPORTED WHEN NECESSARY WITH SUPPLEMENTAL OXYGEN AND/OR ASSISTED VENTILATION.
In cases of severe cardiopulmonary depression, discontinue drug administration, ensure the existence of a patent airway and initiate assisted or controlled ventilation with pure oxygen. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other techniques as appropriate for the observed abnormality.
Due to sevoflurane’s low solubility in blood, increasing the concentration may result in rapid changes in anesthetic depth and hemodynamic changes (dose dependent decreases in respiratory rate and blood pressure) compared to other volatile anesthetics. Excessive decreases in blood pressure or respiratory depression may be corrected by decreasing or discontinuing the inspired concentration of sevoflurane.
Potassium hydroxide containing CO2 absorbents (e.g. BARALYME®) are not recommended for use with sevoflurane.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
SevoFlo is indicated for induction and maintenance of general anesthesia in dogs.
History
There is currently no drug history available for this drug.
Other Information
SevoFlo (sevoflurane) is a volatile liquid, is a halogenated general inhalation anesthetic drug. Its chemical name is fluoromethyl 2,2,2-trifluoro-l-(trifluoromethyl) ethyl ether, and its structural formula is:
Sevoflurane Physical Constants are:
| Molecular Weight | 200.05 | |
| Boiling Point at 760 mm Hg | 58.6°C | |
| Specific Gravity at 20 °C | 1.520 - 1.525 g/mL | |
| Vapor Pressure in mm Hg | at 20 °C | 157 |
| at 25°C | 197 | |
| at 36°C | 317 | |
| Distribution Partition Coefficients | at 37°C: | |
| Blood/Gas | 0.63 - 0.69 | |
| Water/Gas | 0.36 | |
| Olive Oil/Gas | 47 - 54 | |
| Brain/Gas | 1.15 | |
| Mean Component/Gas Partition Coefficients at 25°C for Polymers Used Commonly in Medical Applications: | ||
| Conductive rubber | 14.0 | |
| Butyl rubber | 7.7 | |
| Polyvinyl chloride | 17.4 | |
| Polyethylene | 1.3 |
Sevoflurane is nonflammable and nonexplosive as defined by the requirements of International Electrotechnical Commission 601-2-13.
Sevoflurane is a clear, colorless, stable liquid containing no additives or chemical stabilizers. Sevoflurane is nonpungent. It is miscible with ethanol, ether, chloroform and petroleum benzene, and it is slightly soluble in water. Sevoflurane is stable when stored under normal room lighting condition according to instructions.
Sources
Sevoflo Manufacturers
-
Abbott Laboratories
![Sevoflo (Sevoflurane) Inhalant [Abbott Laboratories]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Sevoflo | Impax Generics
Prior to initiating methylTESTOSTERone, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.
MethylTESTOSTERone capsules are administered orally. The suggested dosage for androgens varies depending on the age, sex, and diagnosis of the individual patient. Dosage is adjusted according to the patient's response and the appearance of adverse reactions.
Replacement therapy in androgen-deficient males is 10 to 50 mg of methylTESTOSTERone daily. Various dosage regimens have been used to induce pubertal changes in hypogonadal males, some experts have advocated lower dosages initially, gradually increasing the dose as puberty progresses with or without a decrease to maintenance levels. Other experts emphasize that higher dosages are needed to induce pubertal changes and lower dosages can be used for maintenance after puberty. The chronological and skeletal ages must be taken into consideration both in determining the initial dose and in adjusting the dose.
Doses used in delayed puberty generally are in the lower range of that given above, and for a limited duration, for example 4 to 6 months.
Women with metastatic breast carcinoma must be followed closely because androgen therapy occasionally appears to accelerate the disease. Thus, many experts prefer to use the shorter acting androgen preparations rather than those with prolonged activity for treating breast carcinoma, particularly during the early stages of androgen therapy. The dosage of methylTESTOSTERone for androgen therapy in breast carcinoma in females is from 50 to 200 mg daily.
Login To Your Free Account